Literature DB >> 9535246

Safety and immunogenicity of the Towne strain cytomegalovirus vaccine.

S P Adler1, S H Hempfling, S E Starr, S A Plotkin, S Riddell.   

Abstract

BACKGROUND: Women with naturally acquired serum antibodies to cytomegalovirus (CMV) are usually protected against both frequent secondary infection and giving birth to infants severely affected by intrauterine CMV infection.
OBJECTIVE: To determine the feasibility of using a live attenuated strain of CMV (Towne) to achieve immunity similar to that provided by wild-type infection, we evaluated a new lot of the Towne strain of CMV in 3 open label trials involving 68 men, 63 women of childbearing age and 13 children, respectively.
RESULTS: Mild local reactions occurred among approximately one-third of subjects. There were no systemic reactions. All 45 subjects tested developed lymphoproliferative responses to CMV. CD8+ class I-restricted cytotoxic T cell responses specific for CMV antigens were detected in three of four subjects and persisted for 6 months. Neutralizing titers were maximal at 2 to 4 months postimmunization, were dose-dependent and were comparable to those induced by natural infection.
CONCLUSION: These results support further evaluation of the Towne strain of CMV in women at risk for acquiring CMV infection during pregnancy or among children transmitting CMV to pregnant women.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9535246     DOI: 10.1097/00006454-199803000-00006

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  23 in total

1.  Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.

Authors:  Corinna La Rosa; Jeff Longmate; Simon F Lacey; Teodora Kaltcheva; Rahul Sharan; Denise Marsano; Peter Kwon; Jennifer Drake; Brenda Williams; Sharon Denison; Suenell Broyer; Larry Couture; Ryotaro Nakamura; Sanjeet Dadwal; Morris I Kelsey; Arthur M Krieg; Don J Diamond; John A Zaia
Journal:  J Infect Dis       Date:  2012-03-07       Impact factor: 5.226

Review 2.  Priorities for CMV vaccine development.

Authors:  Philip R Krause; Stephanie R Bialek; Suresh B Boppana; Paul D Griffiths; Catherine A Laughlin; Per Ljungman; Edward S Mocarski; Robert F Pass; Jennifer S Read; Mark R Schleiss; Stanley A Plotkin
Journal:  Vaccine       Date:  2013-10-13       Impact factor: 3.641

Review 3.  Prospects of a vaccine for the prevention of congenital cytomegalovirus disease.

Authors:  Bodo Plachter
Journal:  Med Microbiol Immunol       Date:  2016-08-12       Impact factor: 3.402

Review 4.  Synthetic DNA approach to cytomegalovirus vaccine/immune therapy.

Authors:  Stephan J Wu; Daniel O Villarreal; Devon J Shedlock; David B Weiner
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 5.  CMV Infection in Pediatric IBD.

Authors:  Anat Yerushalmy-Feler; Sharona Kern-Isaacs; Shlomi Cohen
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

6.  Clinical significance of cytomegalovirus infection in patients with inflammatory bowel disease.

Authors:  Elena Garrido; Elisa Carrera; Rebeca Manzano; Antonio Lopez-Sanroman
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

7.  A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men.

Authors:  Stuart P Adler; Anne-Marie Manganello; Ronzo Lee; Michael A McVoy; Daniel E Nixon; Stanley Plotkin; Edward Mocarski; Josephine H Cox; Patricia E Fast; Pavlo A Nesterenko; Susan E Murray; Ann B Hill; George Kemble
Journal:  J Infect Dis       Date:  2016-08-11       Impact factor: 5.226

8.  Prevention of maternal cytomegalovirus infection: current status and future prospects.

Authors:  Jessica L Nyholm; Mark R Schleiss
Journal:  Int J Womens Health       Date:  2010-08-09

9.  Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.

Authors:  Daniel C Freed; Qi Tang; Aimin Tang; Fengsheng Li; Xi He; Zhao Huang; Weixu Meng; Lin Xia; Adam C Finnefrock; Eberhard Durr; Amy S Espeseth; Danilo R Casimiro; Ningyan Zhang; John W Shiver; Dai Wang; Zhiqiang An; Tong-Ming Fu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

10.  A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques.

Authors:  Felix Wussow; Yujuan Yue; Joy Martinez; Jesse D Deere; Jeff Longmate; Andreas Herrmann; Peter A Barry; Don J Diamond
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.